A Randomized, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Qapzola (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients With Low- To-Intermediate-Risk NMIBC (CONQUER)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Mar 2019
Price : $35 *
At a glance
- Drugs Apaziquone (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- Acronyms CONQUER
- Sponsors Spectrum Pharmaceuticals
- 05 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.
- 25 Jul 2017 New trial record